중증근무력증(MG) : 세계 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(주요 32개 시장, 2025-2035년)

Global Myasthenia Gravis (MG) Market Outlook

Thelansis's "Global Myasthenia Gravis (MG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Myasthenia Gravis treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Myasthenia Gravis (MG) Overview

Myasthenia Gravis is a chronic autoimmune neuromuscular disorder marked by fluctuating skeletal muscle weakness. It is driven by autoantibodies against the acetylcholine receptor, muscle-specific kinase, or LRP4 that disrupt signal transmission at the neuromuscular junction. Patients present with ptosis, diplopia, bulbar symptoms, or proximal limb weakness. Modern management pairs baseline acetylcholinesterase inhibitors like pyridostigmine and traditional immunosuppressants with rapid, targeted therapies. The treatment landscape centers heavily on neonatal Fc receptor blockers; alongside nipocalimab, the FDA expanded the approval of efgartigimod variants to cover all adult generalized myasthenia gravis serotypes, including triple-seronegative and MuSK-positive presentations. Furthermore, targeted choices include the CD19-directed B-cell depleting antibody inebilizumab alongside complement inhibitors like eculizumab, ravulizumab, or zilucoplan for severe, refractory cases. Thymectomy remains a key surgical intervention for non-thymomatous acetylcholine receptor-positive patients to support long-term remission. Careful monitoring for myasthenic crisis, medication compliance, and multidisciplinary care optimize functional outcomes.

Key Highlights

• In Germany, diagnosed Myasthenia Gravis cases are projected to increase from 7,567 in 2025 to 8,099 by 2035.
• Myasthenia Gravis is a rare autoimmune neuromuscular disorder causing fluctuating muscle weakness and fatigue.
• Despite available therapies, many patients continue to experience inadequate disease control and frequent exacerbations.
• Significant unmet need remains for targeted therapies that provide sustained symptom control and improved quality of life.

Market Overview

• The Germany Myasthenia Gravis market is projected to grow from $95M in 2025 to $200M by 2035.
• Market growth is driven by:
• Increasing adoption of targeted biologics and complement inhibitors
• Expanding development of novel immunotherapies
• Future growth will depend on therapies offering durable disease control with improved safety profiles.

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle Ea

Companies Mentioned

• ImmunAbs Inc.
• NMD Pharma A/S
• Kyverna Therapeutics
• Amgen
• Janssen Research & Development, LLC
• UCB Biopharma SRL
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Harbour BioMed (Guangzhou) Co. Ltd.
• Argenx
• COUR Pharmaceutical Development Company, Inc.
• RemeGen Co., Ltd.
• Aurinia Pharmaceuticals Inc.
• Vertex Pharmaceuticals Incorporated
• Dianthus Therapeutics
• Cartesian Therapeutics
• Ra Pharmaceuticals, Inc.
• Clinique Neuro-Outaouais
• Kite, A Gilead Company
• Arcellx, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)